Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.

Abstract: The invention relates to methods and products for enhancing and improving recovery of lost memories. In particular the methods are accomplished through the increase of histone acetylation.

Abstract: The invention generally relates to various oil formulations for protecting plants from nematodes and other pathogens. The invention provides specific formulations which do not require the use of chemical additives. These formulations have low phytotoxicity and low volatility. Also, methods of applying the formulations for agricultural use are disclosed.

Abstract: The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of T. nucifera or abietane diterpenoid compound or terpenoid compound isolated from the same as an effective ingredient. T. nucifera extracts or abietane diterpenoid compound or terpenoid compound isolated from the same of the present invention not only shows excellent anti-oxidative activity to LDL but also effectively inhibits ACAT activity. Further, T. nucifera extracts of the present invention reduce blood LDL cholesterol and total cholesterol. Therefore, the composition of the present invention can be effectively used for the prevention and the treatment of cardiovascular diseases including hyperlipidemia and atherosclerosis caused by the LDL oxidation and the synthesis and accumulation of cholesteryl ester.

Abstract: The present invention pertains to substances of the formula (I) wherein X is O or S; and R1-R4 are defined in the claims as inhibitors of glyoxalase I and/or II, pharmaceutical compositions comprising one or more compounds according to formula (I) and the use of one or more compounds according to formula (I) for the treatment of diseases associated with increased glycolytic metabolism. In one embodiment, the disease is a fungal infection.

Abstract: Ester compounds of the formula I-a wherein R1 is selected from OH, NH2 and NH3+X?, wherein X is an inorganic anion, wherein R2 is a singly-branched saturated or unsaturated aliphatic hydrocarbon moiety selected from C7-C15, wherein R5 is selected from H, and a linear saturated or unsaturated aliphatic hydrocarbon moiety selected from C6-C14, and wherein R2 and R5 together have a total of 7 to 15 carbon atoms; that are useful as antibacterial or antifungal compounds in consumer products.

Abstract: The present invention relates to a process for the cosmetic treatment of wrinkled skin, comprising the topical application to the said skin of a composition comprising, in a physiologically acceptable medium, at least one ester of ((dialkylamino)alkoxy)ethanol of formula (I): It also relates to novel compounds belonging to the formula (I) and corresponding to the formulae (II) and (III): and to the cosmetic compositions comprising them.

Abstract: The present invention relates to lotion compositions comprised on a body facing surface of an absorbent article such as a diaper, training pants or adult incontinence product. The lotion composition may be used for reducing the adherence of feces or menses to the human skin. The lotion composition comprises at least two compounds wherein one first compound is liquid at 25° C. and at least one second component which is solid at 25° C. An effective amount of the lotion composition is comprised on a body facing surface of an absorbent article which is intended to be worn by a wearer.

Abstract: In certain aspects the invention features novel compositions and pharmaceutical preparations of the same. In certain embodiments, the compositions comprise ?- and/or ?-boswellic acid and/or their C-acetates in an amount greater than 65% by weight.

Abstract: Disclosed herein are substituted cyclohexanone-based NMDA receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: A drag may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

Abstract: D-(threo)-1-aryl-2-disubstitutedacylamido-3-fluoro-1-propanol compounds compounds and analogues thereof (“Fenicol Compounds”), compositions comprising an effective amount of a Fenicol Compound, and methods for treating or preventing a bacterial infection in an animal comprising administering to an animal in need thereof an effective amount of a Fenicol Compound are disclosed.

Abstract: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective amount of the above synergistic and residual pesticidal compositions to a locus where pest control is desired.

Abstract: This document provide materials and methods for treating patients infected with a spore-forming bacteria and materials and methods for preventing development of Clostridium difficile-associated disease.

Abstract: An antimicrobial composition containing a cationic polymer having limited antimicrobial activity (such as a hydrophobically-modified quaternary ammonium cellulose ether) and an antimicrobial compound (such as one or more compounds selected from the group consisting of diiodomethyl-para-tolylsulfone, ortho-phenylphenol, sodium pyrithione, zinc pyrithione, 3-iodo-2-propynylbutylcarbamate, 2-methyl-4-isothiazolin-3-one, 1,2-benzisothiazolin-3-one, 2-n-octyl-4-isothiazolin-3-one, 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride, 2-(4-thiazolyl)-benzimidazole, ?-bromo-?-nitrostyrene, 2,4,4?-trichloro-2-hydroxyphenyl ether, chloroxylenol, chlorocresol, para-tert-amylphenol, N-(4-chlorophenyl)-N?-(3,4 dichlorophenyl)-urea, and para-hydroxybenzoic acid esters). The growth of microorganisms (such as Pseudomonas aeruginosa) can be inhibited by exposing the microorganism to such a composition.

Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: A composition for hyperuricemia disease or a related disorder, use thereof and method of using thereof are provided.

Abstract: Stable and non-hygroscopic L-carnitine salts of organic acids are provided, each of which is present as a true complex salt, having the formula: wherein Z is acetate, propionate, or butyrate. In addition, processes for the preparation of these compounds are provided, together with the use of these compounds as a source of both L-carnitine and the calcium ion in nutrition or as a pharmaceutical active ingredient having therapeutic pharmacological activity.

Abstract: The subject invention provides methods for using TRPM8 receptors as a therapeutic target for identifying effective methods or compounds useful in the diagnosis or treatment of respiratory diseases or conditions. In certain embodiments, compositions that are identified using the methods of the invention are administered to a patient to diagnose or treat a respiratory disease or condition. In a preferred embodiment, TRPM8 receptor blockers are identified and administered, in accordance with the subject invention, to treat a patient with a respiratory disease, such as asthma.

Abstract: Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H.

Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.

Abstract: A biodegradable polymer comprising a spherical poly (?-caprolactone-co-methylmethacrylate) used in a therapeutic agent for skin diseases and a method for preparing the same, and a method for preparing the therapeutic agent for skin diseases having the particle size of 50 to 100 nm and a spherical shape comprising the poly (?-caprolactone-co-methylmethacrylate) and salicylic acid.

Abstract: The uses of mono acetyl diacyl glycerol derivatives extracted from deer antler for immunomodulating agent disclosed. Medical supplies and health foods containing the same as an effective ingredient also disclosed. Mono acetyl diacyl glycerol derivatives shows significantly effect for immuno modulation including immune enhancing. In the case of inducing cancer in a hamster by injecting cancer cell line, cancer development was delayed by activating lymphocytes, monocytes, and dendritic cells that are important factors to promote immunity and apoptosis of cancer cell was induced by promoting cytotoxicity of immune cell against cancer cell. Also in the case of mouse induced septic shock, it shows 100% survival rate even after lapse of 120 hours by control of immune function and suppression effect apoptosis.

Abstract: A composition for lowering internal lipid in a subject which contains a capsinoid substance represented by the following formula wherein n is an integer from 0 to 10. Methods of using the compositions are disclosed and include administering to a subject in need of such treatment.

Abstract: Methods are provided for promoting longevity and decreasing the incidence of ageing associated pathologies (e.g. cancer) by the administration of one or more of the following LFFA: linoleic, oleic, and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also in promoting longevity and delaying the onset of age associated disorders. In addition, interventions including LFFA and CoA LFFA formulations are described which protect the organism from acute physical stress, tissue damage, and hypoxia, either due to trauma or secondary to surgical procedures.

Abstract: A method of reducing hair growth includes topical application of a TRPM8 and/or a TRPA1 agonist, alone or in conjunction with heat.

Abstract: A composition for topical application to the skin comprising at least one unsolubilized oil-soluble hydrophobic cooling ingredient having a heat of fusion above 100 J/g and a melting point substantially near body temperature, a polymeric emulsifier in which the cooling ingredient is not soluble, and a cosmetically acceptable carrier.

Abstract: This invention provides compounds of formula A and formula B which are modulators of potassium ion channels and are useful for the treatment of seizure disorders.

Abstract: Medicaments containing shikonin compounds and salts thereof including shikonin and alkannin are used for treatment of virus infections, mycoplasma infections and malignant tumor.

Abstract: The invention relates to acylhydrazone derivatives of formula (I), which are SGK inhibitors and can be used for the treatment of diseases and afflictions associated with SGK, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systematic and pulmonary hypertension, cardiovascular diseases and kidney diseases and in general for all types of fibroses and inflammatory processes. In said formula: R1 and R5 independently of one another represent H, OH, OA, OAc or methyl; R2, R3, R4, R6, R7, R8, R9 and R10 independently of one another represent H, OH, OA, OAc, OCF3, Hal, NO2, CF3, A, CN, OSO2CH3, SO2CH3, NH2, or COOH; R11 represents H or CH3; A represents an alkyl comprising 1, 2, 3, or 4 C atoms; X represents CH2, CH2CH2, OCH2 or —CH(OH)— and Hal represents F, Cl, Br or I.

Abstract: The use is described of a compound of the formula (I) or (ent-I) or a blend consisting of two, three or more compounds of the formula (I) or (ent-I) (a) as a cooling substance for non-therapeutic purposes or (b) for the production of a medicament, wherein in each of the formulae (I) and (ent-I) R1, R2, R3, R4 and R5 mutually independently in each case mean hydrogen or a linear, branched or cyclic, saturated or unsaturated hydrocarbon residue having 1 to 4 carbon atoms.

Abstract: This invention provides novel methods of treatment to ameliorate or prevent cognitive disorder/dysfunction in pre- or asymptomatic subject having one or more mutations in the Huntington gene. The methods involve increasing the expression or activity of the neurotrophin BDNS in the brain of said subject.

Abstract: A one part, solids containing decontamination blend composition comprises a solid acetyl donor coated with a compound that protects it from hydrolysis, a peroxygen source, optionally a catalyst, optionally a surfactant, and optionally a buffer. The decontamination blend composition is generally in a dry powder, particle, etc form or in a tablet, pill, etc form and is complete in and of itself in that no additional compounds are required prior to use and is readily distributed as a one package system. Upon the addition of water, a peroxygen compound such as hydrogen peroxide is formed, and peracetic acid is generated under alkaline conditions. The decontamination blend composition is particularly suitable for oxidizing various chemical and biological compounds thereby eradicating the same in situ as on surfaces, clothes, articles, and the like. Representative contaminants include mustard gas, nerve gas, bacterial toxins, anthrax, bird flu, and the like.

Abstract: A smooth, dry-feeling, less-greasy, substantially-odorless, ecotoxicologically-safe, wax-based composition with a melting point above 25° C., comprising one or more wax components selected from dialkyl carbonates, dialkylene carbonates, and mixtures of two or more thereof; less than 10%, by weight, of water; and (c) optionally, one or more components selected from the group consisting of one or more wax or oil components selected from the group consisting of dialkyl ethers, dialkylene ethers, dicarboxylic acids, hydroxyfatty alcohols, and mixtures of two or more thereof, as well as one or more wax-like lipid components, other than those in previously listed, one or more other oil components, liquid at 20° C. and immiscible with water at 25° C.

Abstract: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds. The present invention further provides methods for the use of such compositions for the treatment of renal or cardiovascular disease and/or related conditions.

Abstract: Disclosed are compounds comprising a benzenediol derivative bound to one or more fatty acids. Also disclosed are nutritional supplements, pharmaceutical formulations, delivery devices, and foodstuffs comprising the disclosed compounds. Methods of using the disclosed compounds and compositions to improve health are also disclosed.

Abstract: The present application relates to a cosmetic composition comprising at least one ester corresponding to formula (I) below: R1COOR2 ??(I) in which R1 represents H or a linear or branched hydrocarbon-based radical, and R2 represents a linear or branched hydrocarbon-based radical, with the proviso that: when R2 is a linear hydrocarbon-based radical and R1 is H or a linear hydrocarbon-based radical, then 7?R1+R2?8; and when at least one of R1 and R2 is a branched hydrocarbon-based radical, then 8?R1+R2?10, with the proviso that, when R1 is tert-butyl, then R2 is not isohexyl. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.

Abstract: Embodiments of the present invention include compositions and pharmaceutical compositions comprising citrulline and Hmg-CoA reductase inhibitors. Further embodiments relate to the use of such composition treat subjects and stimulating nitric oxide synthase.

Abstract: The purpose of this invention is: new selenohydroxy acid compounds and their derivatives; their process for the preparation; use of the new compounds as precursors of L(+)-selenomethionine and/or source of selenium in human or animal nutrition, in cosmetics and pharmaceutics; and nutritional, cosmetic and pharmaceutical compositions containing them.

Abstract: The present invention refers to the use of the compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodisplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or phrophylactic treatment of, inter alia, actinic keratosis.

Abstract: Compositions, in particular, for the treatment of the hair or of the skin, comprising at least one compound which is selected from L-carnitine or L-carnitine derivatives and at least one further substance which is selected from the group formed from active ingredients obtainable from the plants of the genus Echinacea, and also taurine and derivatives thereof.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.

Abstract: The present invention relates to the use of a compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of benign prostatic hyperplasia, Barrett's disease, asthma, skeletal muscle and tendon repair, Crohn's disease, ulcerative colitis and leishmaniasis.

Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis.

Abstract: The present invention generally relates to enhancement and recovery of muscle performance in a state of stress induced by physical exercise, disease or trauma. More particularly the invention relates to means for improved muscle performance and for providing more efficient muscle recovery after physical or traumatic stress. The present invention also relates to means for increasing body mass, including muscle mass, and especially lean body mass. Specifically, the invention relates to a nutrient supplement and the use thereof for enhanced recovery and/or performance of the muscles. The invention further relates to a method for improving muscle performance in and muscle recovery from a state of stress induced by physical exercise, disease or trauma.

Abstract: A compound of formula: wherein X is a C2-10 spacer, and R is a substituted or unsubstituted C6-30 aryl, a substituted or unsubstituted C5-30 heteroaryl, or Where R? and R? are independently a substituted or unsubstituted aryl or a substituted or unsubstituted alkyl, wherein said compound is a vitamin D receptor (VDR) antagonist, a compound comprising same, and a method of treating a patient for a disease that can be treated prophylactically or therapeutically by administration of a VDR antagonist, which method comprises administering an effective amount of aforementioned compound or composition, whereupon the patient is treated prophylactically or therapeutically for the disease.

Abstract: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective amount of the above synergistic and residual pesticidal compositions to a locus where pest control is desired.

Abstract: A method for suppressing undesired viral growth in a host which comprises administering to the host an effective amount of a compound of the formula: wherein R1, R2, R3 and R4 are independently selected from the group consisting of HO—, CH3O— and CH3(C?O) O—. The method is exemplified by inhibiting Tat transactivation of a lentivirus and in suppressing Herpes simplex virus.